Ag85B-ENO1 46-82 therapeutic vaccines enhance anti-tumor immunity by inducing CD8 + T cells and remodeling tumor microenvironment
Fengjun Liu,Huan Huang,Xiaoli Yang,Shasha Jiang,Aotian Xu,Zhongjie Yu,Jun Li,Meng Yu,Yunyang Wang,Bin Wang
DOI: https://doi.org/10.1016/j.intimp.2024.111707
IF: 5.714
2024-02-22
International Immunopharmacology
Abstract:Lung cancer is the leading cause of cancer-related morbidity and mortality in China. However, the effect of traditional cancer treatment is limited. Herein, we designed a therapeutic cancer vaccine based on the tumor-associated antigen mENO1, which can prevent lung cancer growth in vivo, and explored the underlying mechanism of Ag85B-ENO1 46-82 therapy. Lewis lung carcinoma (LLC) tumor-bearing immunocompetent C57BL/6 mice that received Ag85B-ENO1 46-82 treatment showed antitumor effect. Further, we detected CD8 + T, CD4 + T in LLC-bearing C57BL/6 mice to understand the impact of Ag85B-ENO1 46-82 therapy on antitumor capacity. The Ag85B-ENO1 46-82 therapy induced intensive infiltration of CD4 + and CD8 + T cells in tumors, increased tumor-specific IFN-γ and TNF-α secretion by CD8 + T cells and promoted macrophage polarization toward M1 phenotype. Flow cytometric analysis revealed that CD8 + T effector memory (TEM) cells and central memory (TCM) cells were upregulated. qPCR and ELISA analysis showed that the expression of IFN-γ and TNF-α were upregulated, whereas of IL1β, IL6 and IL10 were downregulated. This study demonstrated that Ag85B-ENO1 46-82 vaccine augmented antitumor efficacy, which was CD8 + T cells dependent. Our findings paved the way for therapeutic tumor-associated antigen peptide vaccines to enhance anti-tumor immunotherapy for treatment of cancer.
pharmacology & pharmacy,immunology